



Configuring an Epic[®] EHR to support ordering of NexoBrid[®] (anacaulase-bcdb)

Please see **IMPORTANT SAFETY INFORMATION** on pages 3-5 and [Full Prescribing Information](#) for NexoBrid.

Disclaimer

The information contained herein is intended for background and educational purposes only and provides instructions to assist with ordering NexoBrid within the approved Indication, Important Safety Information, and use that is consistent with the Full Prescribing Information. It is not intended to provide medical advice or direction.

All decisions, including treatment decisions, should always be up to the discretion of a healthcare provider and individual, as each individual's situation will vary along with each patient's electronic health records.

The information is intended to assist healthcare providers and health systems when configuring their EMR/EHR systems. Vericel does not endorse any specific system however it is using EPIC as an example. This should not replace any additional direction provided by any internal support teams.

Each user shall be solely responsible for implementation, testing and monitoring of the EMR/EHR system, as each system will vary and the information provided within is not guaranteed to work for all systems.

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

NexoBrid Important Safety Information¹

INDICATION

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for:

- Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
- Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal

Please see Full Prescribing Information.

1. NexoBrid Prescribing Information. Vericel Corporation. Cambridge, MA. 2024.

NexoBrid Important Safety Information¹ (cont'd)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

WARNINGS AND PRECAUTIONS

Hypersensitivity reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NEXOBRID (if applicable) and initiate appropriate therapy.

Healthcare personnel should take appropriate precautions to avoid exposure when preparing and handling NEXOBRID (e.g., gloves, surgical masks, other protective coverings, as needed).

Please see Full Prescribing Information.

1. NexoBrid Prescribing Information. Vericel Corporation. Cambridge, MA. 2024.

NexoBrid Important Safety Information¹ (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Coagulopathy

Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.

ADVERSE REACTIONS

The most common adverse reactions (>5%) in adults were pruritus, pyrexia, wound complication, anemia, vomiting and insomnia. The most common adverse reactions (>5%) in pediatric patients were pruritus, pyrexia and vomiting.

USE IN SPECIAL POPULATIONS

Geriatric Use

Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

1. NexoBrid Prescribing Information. Vericel Corporation. Cambridge, MA. 2024.

Contents




Product Illustration

- ◆ High-level Process for Providers Interested in Ordering NexoBrid® in Epic®
- ◆ Core Medication Build Instructions
- ◆ Build Optimization Instructions
- ◆ Physician Build Instructions (Optional)

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

The Epic build process for a new hospital pharmaceutical in Epic involves two phases: core medication build and build optimization



Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

High-level Process for Providers Interested in Ordering NexoBrid® in Epic®

General information:

- Build outlined in this document will help users order NexoBrid for Inpatient and Observation patients in the hospital
- These steps should be completed after your organization's Pharmacy and Therapeutics (P&T) Committee has approved NexoBrid
- Every healthcare organization and every instance of Epic is different, so the instructions may not be identical to your use case; your IT team should be able to adapt this document's instructions to meet the specific needs of your organization

To complete core medication build so NexoBrid is orderable in Epic, your Willow Inpatient team should:

1. Load and update medication records in Epic
2. Add NexoBrid to the Central Pharmacy and Preference Lists
3. Manage testing of updated records and migrate to production



Product is now orderable in Epic

Core medication build

To optimize the build, your EpicCare Inpatient Orders team may need to do some or all of the following:

1. Add NexoBrid to existing SmartGroups or create a new SmartGroup
2. Add NexoBrid to existing Order Sets or create a new Order Set
3. Build a Best Practice Advisory to suggest NexoBrid for applicable patients
4. Manage testing of updated records and migrate to production

Build optimization

Surgeons at your organization may want to do the following, to help simplify NexoBrid ordering and documentation:

1. Add NexoBrid to User Preference Lists
2. Create a SmartPhrase (aka a "dot phrase") for documenting NexoBrid administration in a Procedure Note

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.



Core Medication Build Instructions

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

1. Load and update Medication Records in Epic

General information:

- To allow the ordering of medications in Epic, the medication records (NDC and ERX files) must first exist
- Your NexoBrid champion should provide you a completed Epic build checklist describing how NexoBrid should be built; if they have not provided you with this checklist, a blank copy, including Vericel's build considerations, is included in the appendix of this document
- Most organizations regularly download medication data from a vendor but if your organization manually builds simple medications, work with your pharmacy to build NexoBrid according to the prescribing instructions found [here](#)

If your organization loads medications from a major vendor like Medi-Span or First Databank (FDB) then you should:

1. Confirm that NDC and ERX records exist for NexoBrid:
 - a) 5 g of lyophilized powder (containing 4.85 grams of anacaulase-bcdb) mixed in 50 g gel vehicle; NDC package code: 69866-2005-3
2. If this NDC and/or ERX record does not exist, perform a new med load per your organization's policies
3. Open the NexoBrid ERX record and update the Dose options, Admin Instructions, and/or Order Instructions as outlined by the NexoBrid champion

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

An example of a NexoBrid order in Epic is provided for reference

anacaulase-bcdb (NEXOBRID) 8.8 % topical gel Accept Cancel

Order Instructions:
Indicate affected area in administration instructions.
One 55 g jar contains 5 g lyophilized powder + 50 g gel vehicle.
One 55 g jar of anacaulase-bcdb per 2.5% BSA to be treated.

DO NOT exceed 15% BSA in a single treatment or 20% BSA (40 g lyophilized powder) over two treatments.

Reference Links:

Dose: g 5 g 10 g 15 g 20 g 25 g 30 g

Route: Topical

Frequency: Once Once

At: Today Tomorrow

Admin Instructions: Apply to ***

Prod. Admin. Inst.: For TOPICAL Use Only. During handling and administration, the use of gloves, masks, or other protective coverings is recommended. Pour anacaulase-bcdb powder into the gel vehicle jar; thoroughly mix using a sterile instrument (eg, tongue depressor, spatula) until mixture is uniform to a final concentration of 8.8%. Prepare within 15 minutes of application. Remove anacaulase-bcdb application from wound area(s) after 4 hours.

Note to Pharmacy: + Add Note to Pharmacy

Priority: Routine

Additional Order Details

During Visit

anacaulase-bcdb (NEXOBRID) 8.8 % topical gel
Topical, Once, today at 1115, For 1 dose
Apply to ***
For TOPICAL Use Only. During handling and administration, the use of gloves, masks, or other protective coverings is recommended. Pour anacaulase-bcdb powder into the gel vehicle jar; thoroughly mix using a sterile instrument (eg, tongue depressor, spatula) until mixture is uniform to a final concentration of 8.8%. Prepare within 15 minutes of application. Remove anacaulase-bcdb application from wound area(s) after 4 hours.

Next Required Accept Cancel

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

Note: Order Instructions, Dose labels, Admin Instructions, and Prod. Admin Inst. do not conform exactly to Vericel's suggestions; instead, they were customized to meet this organization's specific build standards

2. Add NexoBrid to Preference Lists

General information:

- By adding NexoBrid to relevant Preference Lists, providers within your organization will be able to search for and order the product
- Organizations have varied approaches to Preference List build; if these instructions deviate from your organization's approach, follow your organization's approach
- Do not create new Preference Lists to support the ordering of NexoBrid, add it to existing Preference Lists

To add NexoBrid to your Preference Lists:

1. Add NexoBrid to your Central Pharmacy medication list
2. Copy NexoBrid to your Central Pharmacy's linked Preference List
3. Identify other Preference Lists NexoBrid should be added to based on request from NexoBrid champion
4. Add NexoBrid to the department and/or security class profile Preference List(s) requested by NexoBrid champion
 - a) Note: at some organizations, security class profile Preference Lists may be owned by the EpicCare Inpatient Orders or OpTime team

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

3. Manage Testing and Production Migration

General information:

- Below are general guidelines for testing your NexoBrid build and moving it to production; if these general guidelines deviate from your organization's policies, follow your organization's policies

Consider the following sequence of testing and production migration:

1. Build all records listed on the previous pages in POC or BLD (proof of concept build testing environment)
2. Create a single Content Management ticket for all NexoBrid build
3. Migrate records to TST (test environment)
4. Coordinate integrated testing of new build in TST
 - a) Test that your records appear in all expected workflows and that NexoBrid can be ordered, dispensed, and administered
 - b) Perform negative testing using non-burn users and/or departments, to ensure NexoBrid is not orderable
5. Once integrated testing is complete, follow your organization's policies to migrate NexoBrid build to production
6. Perform production testing of NexoBrid build if required by your organization

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.



Build Optimization Instructions

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

1a. Add NexoBrid to Existing SmartGroups

General information:

- SmartGroups are used in Epic as building blocks to create larger Order Sets and SmartSets
- Organizations have varied policies for approving changes to SmartGroups and Order Sets, including committee meetings
- Ensure you are following your organization's policies for clinical approval when completing these steps

To add NexoBrid to existing SmartGroups:

1. Identify the existing SmartGroups in Epic that the NexoBrid champion requested be updated
2. Open your SmartGroup by searching for **SmartGroups** or choosing **SmartGroups** from your Orders Admin dashboard
3. Go to the **Configuration** form, click **Add Item**, and select the appropriate **Item Type**
4. Find the NexoBrid product that your organization uses and click **Accept**
5. If you need to change any Order Composer defaults you can do so, then click **Accept**
6. Repeat steps 3-5 for any nursing communication orders or pain management medications requested by the NexoBrid champion
7. Go to the **General Info** form and add a new Web Information link with these details:
 - a) Title: Using NexoBrid for eschar removal
 - b) URL: <https://www.nexobrid-us.com/how-to-use/>
8. Select **Test Release** from the toolbar, and close the record
9. Repeat 2-8 for each SmartGroup that NexoBrid should be added to

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

1b. Create a New SmartGroup

To create a new NexoBrid SmartGroup:

1. Search for **SmartGroups** or choose **SmartGroups** from your Orders Admin dashboard and go to the **Create** tab
2. Name your SmartGroup and click **Accept** twice
3. Go to the **General Info** form
4. Add relevant synonyms including Burn, Eschar, Debridement, NexoBrid, and Anacaulase
5. Add a Web Information link with these details:
 - a) Title: Using NexoBrid for eschar removal
 - b) URL: <https://www.nexobrid-us.com/how-to-use/>
6. Go to the **Configuration** form, click **Add Item**, and select the appropriate **Item Type**
7. Find the NexoBrid product that your organization uses and click **Accept**
8. If you need to change any Order Composer defaults you can do so, then click **Accept**
9. Repeat steps 6-8 for any nursing communication orders or pain management medications requested by the NexoBrid champion
10. Select **Test Release** from the toolbar, and close the record

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid **Full Prescribing Information** for more information.

2. Add NexoBrid to Order Sets or Create a New Order Set

General information:

- If you added NexoBrid to one or more existing SmartGroups in step 1a, and those SmartGroups are already used in existing Order Sets, you can skip this step
- If you do need to create or change Order Sets, ensure you are following your organization's policies for clinical approval

To add NexoBrid to existing Order Sets:

1. Identify the existing Order Sets in Epic that your NexoBrid champion asked for NexoBrid to be added to
2. Open your Order Set by searching for **Order Sets** or choosing **Order Sets (PRL)** from your Orders Admin dashboard
3. Go to the **Configuration** form and add your SmartGroup to the **Medications** (or similarly named) section
4. Select **Test Release** from the toolbar, and close the record
5. Repeat 2-4 for each Order Set that your SmartGroup should be added to

To create a new Order Set for your SmartGroup:

1. Search for **Order Sets (PRL)** or choose **Order Sets (PRL)** from your Orders Admin dashboard and create a new Order Set
2. On the **General Info** form, update the display name and add relevant synonyms including Burn, Eschar, debridement, NexoBrid, and Anacaulase
3. Go to the **Configuration** form and add your SmartGroup to the **Medications** (or similarly named) section
 - a) Add a Medications section if one was not automatically added when you made your new Order Set
4. Select **Test Release** from the toolbar, and close the record

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

3. Build a BestPractice Advisory to Suggest NexoBrid

General information:

- BestPractice Advisories are versatile tools that can be used to recommend treatments for patients based on various criteria
- It is important to work with your NexoBrid champion to determine how your organization identifies patients that should be treated with NexoBrid, and when in the providers' workflow to show the BestPractice Advisory
 - If your NexoBrid champion wants to identify patients based on ICD-10 codes, consider one or more of the codes found on pages 4-7 of the [NexoBrid reimbursement guide](#)
 - Note: consider only configuring BPAs to suggest NexoBrid passively in navigators, not as a pop-up

To automatically suggest a NexoBrid order for relevant patients:

1. Search for **BestPractice Advisories** or select **BestPractice Advisories** on your dashboard, then go to the **Create** tab
2. BPA build varies dramatically across organizations, but you will most likely need to create three records:
 - a) A BPA Criteria record to include patients for whom NexoBrid should be suggested, as agreed upon by your clinical team
 - b) A BPA Criteria record to include patients who already have a NexoBrid order (which will then be attached using NOT logic)
 - c) A BPA Base record to determine who sees the BPA, when and where it is shown, and what message is displayed
3. After creating these three records, go to the **Criteria** form in your BPA Base record and link both of your Criteria records then apply the logic **1 NOT 2**
4. Release all your BPAs as you create them
5. Reopen any SmartGroup or Order Set you want to automatically suggest, go to the **Criteria** form, and add your BPA Base

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid [Full Prescribing](#)

[Information](#) for more information.

4. Manage Testing and Production Migration

General information:

- Below are general guidelines for testing your NexoBrid build and moving it to production; if these general guidelines deviate from your organization's policies, follow your organization's policies

Consider the following sequence of testing and production migration:

1. Build all records listed on the previous pages in POC or BLD
2. Create a single Content Management ticket for all NexoBrid SmartGroup, Order Set, and BPA build
3. Migrate records to TST
4. Coordinate integrated testing of new build in TST
 - a) Test that your records appear in all expected workflows and that NexoBrid can be ordered, dispensed, and administered
 - b) Perform negative testing using non-burn users, departments, and patients to ensure NexoBrid is not recommended in scenarios where patients should not receive it
 - c) Test the "Using NexoBrid for eschar removal" web link you added to your SmartGroups; if the link does not work, contact your Client Systems team
5. Once integrated testing is complete, follow your organization's policies to migrate NexoBrid build to production
6. Perform production testing of the "Using NexoBrid for eschar removal" web link you added to your SmartGroups; if the link does not work, contact your Client Systems team
7. Perform production testing of any other NexoBrid build as required by your organization
8. Release all unreleased records

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.



Physician Build Instructions (Optional)

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

1. Consider Adding NexoBrid to User Preference Lists

General information:

- Physicians can add medications to their personal user Preference Lists to make ordering faster and easier
- These steps can be completed once your Willow Inpatient team has built or imported medication records and added the medication to your Central Pharmacy Preference List

To add a medication to your user Preference List:

1. Open any patient as you normally would, place a new order, search for the medication, and select the product
2. Edit the order details as needed, and click **Accept**
3. Before signing your order, click the star icon to add it to your preference list
4. In the Add to Preference List window, add any other order details that you want to be included by default when you order the medication, and click **Accept**

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.

2. Consider creating a SmartPhrase (aka a “dot phrase”) for documenting NexoBrid administration in a Procedure Note

General information:

- Physicians can create SmartPhrases to simplify procedure documentation
- These steps can be completed at any time

To create a new medication documentation SmartPhrase:

1. From your Epic home screen, click on the **Epic** menu button, then **Tools**, then **SmartPhrase Manager**
2. Choose **New Phrase**
3. Name your SmartPhrase something easy to remember that will not be confused with other SmartPhrases
4. Under **Sharing**, add any other users who may also document the administration of the medication
5. Add body text for your SmartPhrase (see next page for a sample)
6. Click **Save**
7. Click **Accept**

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.



Appendix: Epic Build Checklist

Please see the **IMPORTANT SAFETY INFORMATION** on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.

NexoBrid champion should provide these core build requirements to make NexoBrid orderable in Epic

Important - Information may only be completed by Facility/Burn Center staff only.

Illustrative example, actual considerations may vary by facility

Which dose options should be available when ordering NexoBrid for a patient?

- 5 g of enzyme (1 vial of 5 g)
- 10 g of enzyme (2 vials of 5 g)
- 15 g of enzyme (3 vials of 5 g)
- 20 g of enzyme (4 vials of 5 g)
- 25 g of enzyme (5 vials of 5 g)
- 30 g of enzyme (6 vials of 5 g)

What Admin Instructions should be included in NexoBrid orders by default?

- From Prescribing Information:** Prepare NexoBrid at the patient's bedside within 15 minutes of the intended application. Using aseptic technique, mix NexoBrid lyophilized powder and gel vehicle as follows. Precautions should be taken to avoid exposure during preparation and handling (e.g., gloves, surgical masks, other protective coverings, as needed). In the event of inadvertent skin exposure, rinse NexoBrid off with water to reduce the likelihood of skin sensitization.

1. Pour the NexoBrid lyophilized powder into the gel vehicle jar.
2. Thoroughly mix the NexoBrid lyophilized powder and gel vehicle using a sterile instrument (e.g., tongue depressor or spatula) until the mixture is uniform.

Discard NexoBrid if not used within 15 minutes of preparation, as the enzymatic activity of the product decreases progressively following mixing.

- Custom Instructions: _____

What Order Instructions should be included in NexoBrid orders by default?

- From Prescribing Information:** NexoBrid is only to be administered by a healthcare provider. Healthcare providers should take precautions to avoid exposure to NexoBrid during preparation and handling (e.g., use of gloves, surgical masks, other protective coverings, as needed).

- Custom Instructions: _____

Which users, user types (security classes), or departments should be able to order NexoBrid?

If NexoBrid Order Sets are required, NexoBrid champion should provide this information

Important - Information may only be completed by Facility/Burn Center staff only.

Illustrative example, actual considerations may vary by facility

Should NexoBrid be added to existing Order Sets, and/or should a new Order Set be created?

- NexoBrid should be added to existing Order Sets described here, or shown in attached screenshots:

- A new Order Set should be created for NexoBrid

Should pain management be added to the Order Set(s)? List which medications should be available and provide any other details about defaults or required options. Consider starting by adding the same medications you use for an extensive burn wound dressing change.

- Oral pain management medications:

- IV pain management medications:

- Nerve blocks and/or other Injectable pain management medications:

- Other pain management medications:

Note: Pain management options listed here are not exhaustive and broad categories of medication types are provided as an illustrative example only

Should a nursing communication order be added to the Order Set(s)? What should the default instructions be?

- From Prescribing Information:** Gather the following supplies prior to NexoBrid preparation and application. All supplies should be sterile: instrument for mixing (e.g., spatula or tongue depressor), tongue depressor for NexoBrid application, 0.9% Sodium Chloride Irrigation, Occlusive film dressing, Loose, thick fluffy dressing, and bandage
- Custom Instructions or additional nursing communication order:

If NexoBrid should be proactively suggested using BPAs, NexoBrid champion should provide this information

Important - Information may only be completed by Facility/Burn Center staff only.

Illustrative example, actual considerations may vary by facility

How should patients be identified as suitable candidates for NexoBrid?

- Consider** one or more of the ICD-10 codes listed on pages 4-7 of the [NexoBrid reimbursement guide](#)
 - A different approach, described here (note: Epic team will need to evaluate request for feasibility):
-
-

When in your workflow should the BPA be displayed?

- Inpatient Navigators
 - Admission Navigator
 - Transfer Navigator
 - Somewhere else as described here, or shown in attached screenshots (note: Epic team will need to evaluate request for feasibility):
-
-

What text should the BPA contain?

Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid [Full Prescribing Information](#) for more information.



Please see the IMPORTANT SAFETY INFORMATION on pages 3-5 and the NexoBrid Full Prescribing Information for more information.



Vericel Corporation, 160 Sidney Street, Cambridge, MA 02139
©2024 Vericel Corporation. All rights reserved. PP.US.NXB.0207
Vericel® and the Vericel logo are registered trademarks of Vericel Corporation.
NexoBrid® is a registered trademark of MediWound Ltd.

